ARCHIVES

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | March 16, 2007

Download PDF Visit The Full Archive

Related Articles

Pain Relievers Protect Against Breast Cancer

April 25, 2003

In Brief: NCAB Dec. Meeting Includes Biologics Symposium; Epidemiology Center Grant Program Disapproved

November 29, 1985

In Brief: James Wallace Named CALGB Executive Officer; Gritz Receives First Joseph Cullen Award

September 11, 1992

FDA Oncology Division To Develop Papers On Expectations for New Drugs

August 2, 1996

National Academy elects New Members

May 9, 1997

Health Canada Suspends Avastin Approval; CMS Has Taken No Action After FDA Decision

December 2, 2011